HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Dietary Supplement Programs Research, Strategy Official Moves To NPA

Executive Summary

Sibyl Swift is responsible for developing and implementing NPA's educational, regulatory and compliance programs such as SSCI and the NPA Natural Standard. She also will assist members with claim reviews, substantiation and NDI notification policy.

You may also be interested in...



SSCI Offers Benchmarks As Gatekeepers For Supplements To Reach Retail Shelves

FDA’s GMP final rule set uniform standards to ensure quality throughout manufacturing, packaging, labeling and holding of supplements, but Supplement Safety and Compliance Initiative says manufacturing practices continue to vary widely across the industry and the agency cannot inspect every facility. “FDA can’t solve all our problems. I don’t know if FDA knows the number of facilities it needs to inspect to ensure consumer confidence," says Daniel Fabricant, president of SSCI member NPA.

People In Brief: Bayer, NPA, FTC

Dekkers gives Bayer two more years; Hilmas joins NPA; Hobbs directs Rainbow Light science; McSweeney starts at FTC; Bayer’s Mann takes WMSI chair; Archambault leads Ropack development.

Fabricant Ends Eventful Service In FDA Supplement Regulation To Head NPA

Daniel Fabricant will be the CEO of NPA, and leave his post as director of FDA’s Division of Dietary Supplement Programs, the association announced April 8.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149579

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel